Nuclear Innovator Newcleo Valued at 24 Billion in Nasdaq Listing Deal SpaceX Supply Chain Stocks Graded Ahead of Potential IPO Bernstein Initiates Coverage on Six Indian Pharma Stocks Highlights AI and Innovation as Key Drivers JapanChina Trade Chiefs Hold First FacetoFace Talks at APEC Since Dispute Drama Desk Awards Signal Shift in Tony Awards Competitive Landscape Gen Z Bargain Hunters Propel Discount Retail Growth Walmart Ross in Focus California Water Service Group CWT Q1 2026 Earnings EPS Misses Estimates by 705 Amid Cost Pressures HASI Q1 2026 Earnings EPS Beats Expectations Stock Rises Atmus Filtration Technologies Q1 2026 Earnings EPS Beat Drives Positive Momentum AerCap Holdings AER Q1 2026 Earnings EPS Surges Past Estimates by 4294 Shares Dip Slightly Post Holdings Q1 2026 Earnings Strong EPS Beat Masks Mixed Underlying Performance BMRC Q1 2026 Earnings Slight EPS Miss as Bank Navigates Margin Pressure Pegasystems Inc PEGA Edges Higher as Stock Tests Key Resistance Levels RPM International Inc RPM Edges Higher Testing Key Resistance After 170 Gain Icon Energy Corp ICON Slips 511 as Stock Approaches Critical Support at 123 SnapOn SNA Edges Higher as Price Approaches Key Resistance GJO Holds Steady at 2422 as FixedIncome Security Maintains Stability UOB Faces High Court Criticism Over Inconsistent Legal Positions on Late Mortgage Payment Charges INFU Q1 2026 Earnings EPS Surpasses Estimates by 466 Shares Dip Slightly Forward Air Corporation FWRD Surges 94 as Logistics Stock Tests Key Resistance Unisys Corporation UIS Q1 2026 Earnings EPS Beat Surprises as Cost Controls Drive Profitability ABSI Q1 2026 Earnings EPS Beats Estimates Amid Continued Drug Discovery Progress Welltower Q1 2026 Earnings Stellar EPS Beat Bolsters Investor Confidence QNRX Q1 2026 Earnings Beats EPS Estimates Despite No Revenue Stock Declines 062 ATNM Q1 2026 Earnings Actinium Reports NarrowerThanExpected Loss as Pipeline Progress Continues REZI Q1 2026 Earnings Strong EPS Beat Amidst Mixed Market Reaction RLAY Q1 2026 Earnings EPS Misses Consensus PreRevenue Biotech Maintains RD Focus